254 related articles for article (PubMed ID: 24969380)
21. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
23. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Lane HY; Chang YC; Su MH; Chiu CC; Huang MC; Chang WH
J Clin Psychopharmacol; 2002 Feb; 22(1):4-10. PubMed ID: 11799336
[TBL] [Abstract][Full Text] [Related]
24. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
[TBL] [Abstract][Full Text] [Related]
25. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
26. Agitation and psychosis in dementia.
Ballard C
Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
[No Abstract] [Full Text] [Related]
27. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
De Deyn PP; Wirshing WC
J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
29. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
30. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.
Chibnall JT; Tait RC; Harman B; Luebbert RA
J Am Geriatr Soc; 2005 Nov; 53(11):1921-9. PubMed ID: 16274373
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Laks J; Engelhardt E; Marinho V; Rozenthal M; Souza FC; Bacaltchuk J; Stoppe A; Ferreira RC; Bottino C; Scalco M
Arq Neuropsiquiatr; 2001 Dec; 59(4):859-64. PubMed ID: 11733828
[TBL] [Abstract][Full Text] [Related]
33. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
34. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
35. Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Herrmann N; Rivard MF; Flynn M; Ward C; Rabheru K; Campbell B
J Neuropsychiatry Clin Neurosci; 1998; 10(2):220-3. PubMed ID: 9608413
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience of galantamine in dementia: a series of case reports.
Dale MC; Libretto SE; Patterson C; Anderson J; Choudhury T; McCafferty F; McWilliam C; Richardson M
Curr Med Res Opin; 2003; 19(6):508-18. PubMed ID: 14594523
[TBL] [Abstract][Full Text] [Related]
37. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
[TBL] [Abstract][Full Text] [Related]
38. A structured trial of risperidone for the treatment of agitation in dementia.
Lavretsky H; Sultzer D
Am J Geriatr Psychiatry; 1998; 6(2):127-35. PubMed ID: 9581208
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Kongpakwattana K; Sawangjit R; Tawankanjanachot I; Bell JS; Hilmer SN; Chaiyakunapruk N
Br J Clin Pharmacol; 2018 Jul; 84(7):1445-1456. PubMed ID: 29637593
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
Teranishi M; Kurita M; Nishino S; Takeyoshi K; Numata Y; Sato T; Tateno A; Okubo Y
J Clin Psychopharmacol; 2013 Oct; 33(5):600-7. PubMed ID: 23948783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
